BMS’s Plans For Zeposia In Crohn’s Dubious Following Phase III Miss

 
• By Joseph Haas
  
Many arrows missed hitting target mark. Shot miss. Multiple failed inaccurate attempts to hit archery target. Business challenge failure metaphor. Flat cartoon isolated vector object illustration
Bristol Myers Squibb missed its Phase III endpoint in Crohn's with Zeposia • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D